AVID100 in Advanced Epithelial Carcinomas
Stopped early · Phase 1/Phase 2
Conditions studied: Solid Tumor, Adult, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
In brief
Approximately 90 male and female patients with documented solid tumor malignancies of epithelial origin that are locally advanced or metastatic, and either refractory to standard therapy or for whom no standard therapy is available, will be entered into this Phase 1a/2a, multicenter, open-label, dose-escalation, cohort study of AVID100. Phase 2a will include evaluation of patient with EGFR-overexpressing squamous histology non-small cell lung cancer, squamous cell carcinoma of the head and neck, and triple negative breast cancer
Key facts
- Study ID
- NCT03094169
- Run by
- Formation Biologics
- People needed
- 49
- Starts
- 2017-02-01
- Expected to finish
- 2021-01-30
- Last updated by the study team
- 2025-06-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Yale — New Haven, Connecticut, United States
- START Midwest — Grand Rapids, Michigan, United States
- The Tisch Cancer Institute-Mt. Sinai — New York, New York, United States
- Fox Chase — Philadelphia, Pennsylvania, United States
- Texas Oncology Midtown — Austin, Texas, United States
- Texas Oncology-Baylor -Charles A. Sammons Cancer Center — Dallas, Texas, United States
- University of Texas Southwestern Medical Center — Dallas, Texas, United States
- Texas Oncology McAllen — McAllen, Texas, United States
- Texas Oncology NE San Antonio — San Antonio, Texas, United States
- Texas Oncology Tyler — Tyler, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.